Medicus Pharma (MDCX) EBITDA (2024 - 2025)
Medicus Pharma (MDCX) reported EBITDA of -$15.1 million for Q4 2025, down 326.66% on a YoY basis from $6.7 million in Q4 2024, and down 754444650.0% quarter-over-quarter from -$2.0 in Q3 2025.
Medicus Pharma (MDCX) EBITDA (2024 - 2025) Analysis & Trends
Medicus Pharma has reported EBITDA for 2 years, with the latest figure at -$15.1 million in Q4 2025.
- For the quarter ending Q4 2025, EBITDA fell 326.66% year-over-year to -$15.1 million; the trailing twelve-month figure through Dec 2025 stood at -$26.2 million (down 136.82% YoY), and the FY2025 full-year result was -$47.3 million, down 323.94% from the prior year.
- EBITDA for Q4 2025 stood at -$15.1 million, down from -$2.0 in the prior quarter.
- The five-year high for EBITDA was -$2.0 in Q3 2025, with the low at -$15.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.83 Bn |
| 10 | Medicus Pharma | 7.87 Mn | 7.98 Mn | - | -15.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.09 Mn |
| Sep 30, 2025 | -2.00 |
| Jun 30, 2025 | -6.02 Mn |
| Mar 31, 2025 | -5.13 Mn |
| Dec 31, 2024 | -3.54 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -1.71 Mn |